The impact of anti-tumour necrosis factor therapy for rheumatoid arthritis on the use of other drugs and hospital resources in a pragmatic setting.

Musculoskeletal care

Volumn 4, Issue 4, 2006, Pages 204-222

  Sandhu, R S ^a   Treharne, G J ^a   Douglas, K M ^a   Cassim, K ^a   Saratzis, A ^a   Piper, H ^a   Erb, N ^a   Jenkins, D ^a   Tavakoli, M ^a   Deighton, C ^a   Kitas, G D ^a  

^a KEELE UNIVERSITY   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIRHEUMATIC AGENT; IMMUNOLOGIC FACTOR; MONOCLONAL ANTIBODY; TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; FEMALE; HEALTH CARE PLANNING; HUMAN; IMMUNOLOGY; LENGTH OF STAY; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDY; RHEUMATOID ARTHRITIS; UTILIZATION REVIEW;

ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; ANTIRHEUMATIC AGENTS; ARTHRITIS, RHEUMATOID; FEMALE; HEALTH RESOURCES; HUMANS; IMMUNOLOGIC FACTORS; LENGTH OF STAY; MALE; MEDICAL AUDIT; MIDDLE AGED; RETROSPECTIVE STUDIES; TUMOR NECROSIS FACTOR-ALPHA;

EID: 38149049770     PISSN: 14782189     EISSN: None     Source Type: Journal    
DOI: 10.1002/msc.92     Document Type: Article

References (0)